Omnicell Competitors
| OMCL Stock | USD 37.07 2.01 5.14% |
Omnicell vs Goodrx Holdings Correlation
Very good diversification
The correlation between Omnicell and GDRX is -0.5 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Omnicell and GDRX in the same portfolio, assuming nothing else is changed.
Moving against Omnicell Stock
| 0.87 | PNGM | Er Therapeutics | PairCorr |
| 0.78 | GLH | Global Health | PairCorr |
| 0.77 | VSEE | VSee Health | PairCorr |
| 0.72 | HSTM | HealthStream | PairCorr |
| 0.67 | STI | Solidion Technology | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Omnicell's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Omnicell Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Omnicell and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Omnicell and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Omnicell does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Omnicell Stock performing well and Omnicell Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Omnicell's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PGNY | 2.47 | 0.28 | 0.08 | 0.50 | 3.03 | 5.30 | 35.40 | |||
| SDGR | 2.24 | (0.75) | 0.00 | (0.34) | 0.00 | 3.89 | 15.22 | |||
| OMDA | 3.09 | (1.19) | 0.00 | (1.10) | 0.00 | 4.61 | 19.12 | |||
| TDOC | 2.23 | (0.87) | 0.00 | (0.33) | 0.00 | 3.70 | 15.93 | |||
| TXG | 3.31 | 0.45 | 0.15 | 0.42 | 2.84 | 10.23 | 24.44 | |||
| PHR | 2.18 | (1.00) | 0.00 | (0.56) | 0.00 | 2.72 | 28.56 | |||
| UFPT | 2.01 | 0.36 | 0.15 | 0.32 | 2.19 | 4.83 | 17.63 | |||
| ASTH | 3.31 | (0.70) | 0.00 | (0.25) | 0.00 | 6.14 | 31.71 | |||
| SSII | 4.12 | (1.10) | 0.00 | (0.61) | 0.00 | 8.06 | 24.32 | |||
| GDRX | 1.98 | (0.56) | 0.00 | (0.29) | 0.00 | 3.33 | 10.97 |
Cross Equities Net Income Analysis
Compare Omnicell and related stocks such as Progyny, Schrodinger, and Omada Health Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PGNY | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | 661 K | (8.6 M) | 46.5 M | 65.8 M | 30.4 M | 62 M | 54.3 M | 62.5 M | 32.8 M |
| SDGR | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (17.4 M) | (28.4 M) | (24.6 M) | (24.5 M) | (100.4 M) | (149.2 M) | 40.7 M | (187.1 M) | (168.4 M) | (160 M) |
| OMDA | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (72.5 M) | (67.5 M) | (47.1 M) | (54.2 M) | (56.9 M) |
| TDOC | (6 M) | (6 M) | (6 M) | (6 M) | (17 M) | (58 M) | (74.2 M) | (106.8 M) | (97.1 M) | (98.9 M) | (485.1 M) | (428.8 M) | (13.7 B) | (220.4 M) | (1 B) | (901.1 M) | (946.2 M) |
| TXG | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (112.5 M) | (31.3 M) | (542.7 M) | (58.2 M) | (166 M) | (255.1 M) | (182.6 M) | (164.4 M) | (172.6 M) |
| PHR | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (18.2 M) | (15.1 M) | (20.3 M) | (27.3 M) | (118.2 M) | (176.1 M) | (136.9 M) | (58.5 M) | (52.7 M) | (55.3 M) |
| UFPT | 200 K | 10.3 M | 10.9 M | 11.3 M | 7.6 M | 7.6 M | 8 M | 9.2 M | 14.3 M | 19.8 M | 13.4 M | 15.9 M | 41.8 M | 44.9 M | 59 M | 67.8 M | 71.2 M |
| ASTH | (5 K) | (720.3 K) | (8.9 M) | (5 M) | (1.8 M) | (9.3 M) | (9 M) | 25.8 M | 10.8 M | 14.1 M | (23.8 M) | 68.9 M | 45.2 M | 60.7 M | 43.1 M | 49.6 M | 52.1 M |
| SSII | (66.0) | (66.0) | (66.0) | (66.0) | (66.0) | (66.0) | (485 K) | (1 M) | (960.3 K) | (3.4 M) | (1.1 M) | (1.5 M) | (5.6 M) | (20.9 M) | (19.2 M) | (17.2 M) | (16.4 M) |
| GDRX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | 8.8 M | 43.8 M | 66 M | (293.6 M) | (25.3 M) | (32.8 M) | (8.9 M) | 16.4 M | 14.8 M | 15.5 M |
Omnicell and related stocks such as Progyny, Schrodinger, and Omada Health Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Omnicell financial statement analysis. It represents the amount of money remaining after all of Omnicell operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Omnicell Competitive Analysis
The better you understand Omnicell competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Omnicell's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Omnicell's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Omnicell Competition Performance Charts
Five steps to successful analysis of Omnicell Competition
Omnicell's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Omnicell in relation to its competition. Omnicell's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Omnicell in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Omnicell's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Omnicell, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Omnicell position
In addition to having Omnicell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Cap ETFs Thematic Idea Now
Large Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large Cap ETFs theme has 896 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Omnicell Correlation with its peers. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. Anticipated expansion of Omnicell directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Omnicell assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.36) | Earnings Share 0.04 | Revenue Per Share | Quarterly Revenue Growth 0.023 | Return On Assets |
Understanding Omnicell requires distinguishing between market price and book value, where the latter reflects Omnicell's accounting equity. The concept of intrinsic value - what Omnicell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Omnicell's price substantially above or below its fundamental value.
It's important to distinguish between Omnicell's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Omnicell should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Omnicell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.